Pneumonia remains a major killer of children under five, with India having the greatest number of pneumococcal deaths in children aged 1-59 months. WHO and United Nations Children's Fund (UNICEF) have also prioritized reducing child mortality due to pneumonia by 2025. National Biopharma Mission aims to facilitate accelerated development and commercialization of promising novel pneumococcal vaccine candidates. 

Name of grantee

Development Phase Supported

Environmental and Health Risk Management Plan (EHRMP)

TERGENE Biotech Private Limited

Phase II CT

Click Here